auris
medical
report
first
half
financial
results
provide
business
update
thursday
september
hamilton
bermuda
september
auris
medical
holding
nasdaq
ears
company
dedicated
developing
therapeutics
address
important
unmet
medical
needs
neurotology
central
nervous
system
disorders
today
announced
provide
business
update
report
financial
results
first
half
thursday
september
following
announcement
auris
medical
management
team
host
live
conference
call
webcast
eastern
time
pm
central
european
time
participate
conference
call
dial
us
toll
free
international
enter
passcode
live
webcast
conference
call
accessed
investor
relations
section
auris
medical
website
replay
available
approximately
two
hours
following
live
call
auris
medical
auris
medical
biopharmaceutical
company
dedicated
developing
therapeutics
address
important
unmet
medical
needs
neurotology
cns
disorders
company
focused
development
intranasal
betahistine
treatment
vertigo
phase
prevention
weight
gain
somnolence
post
phase
company
developing
nasal
spray
protection
airborne
pathogens
allergens
addition
auris
medical
two
phase
programs
development
acute
inner
ear
hearing
loss
acute
inner
ear
tinnitus
company
founded
headquartered
hamilton
bermuda
main
operations
basel
switzerland
shares
auris
medical
holding
trade
nasdaq
capital
market
symbol
investor
contact
joseph
green
edison
advisor
auris
medical
jgreen
investors
